JERUSALEM, May 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate in the following investor conferences.
| Event: | Jefferies Healthcare Conference |
| Format: | Presentation and 1-on-1 meetings |
| Date: | Wednesday, June 7 |
| Time: | 2:30 p.m. Eastern Time |
| Location: | New York, NY |
| Event: | Sidoti Small-Cap Virtual Conference |
| Format: | Presentation and 1-on-1 meetings |
| Date: | June 14-15 |
| Location: | Virtual |
| Registration: | https://www.meetmax.com/sched/event_94441/investor_reg_new.html?attendee_role_id=SIDOTI_INVESTOR |
| Event: | Citi European Healthcare Conference |
| Format: | 1-on-1 meetings |
| Date: | Thursday, June 22 |
| Location: | Virtual |
About Alpha DaRT™
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
About Alpha Tau Medical, Ltd.
Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
Investor Relations Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.45 |
| Daily Change: | -0.05 -2.00 |
| Daily Volume: | 22,996 |
| Market Cap: | US$170.690M |
March 07, 2024 November 28, 2023 November 20, 2023 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MORE
